Head of Early Discovery

Core responsibilities:

• Define and execute the early discovery strategy aligned with company objectives
• Oversee target identification, validation, and mechanism-of-action studies with a strong focus on oncology and immunology
• Lead strategic initiatives to accelerate drug discovery by leveraging cutting-edge technologies, data-driven decision-making, and innovative scientific approaches
• Manage cross-functional collaborations with internal teams and external partners, including academic institutions and pharmaceutical companies

This role accelerates drug discovery through cutting-edge technologies and data-driven approaches, driving impactful therapies for patients by shaping Recursion's early discovery pipeline and translating programs into later development stages.

Required qualifications:

• PhD in Biology or related discipline
• 10+ years of postdoctoral experience in oncology and immunology
• Proven track record in target identification, validation, and translation into later stages of drug discovery
• Demonstrated ability to embrace and implement modern technologies (e.g., AI) in drug discovery
• Exceptional communication and leadership skills

Compensation and benefits:

• Estimated annual base salary range: $228,800 - $275,000 (USD)
• Eligible for annual bonus and equity compensation
• Comprehensive benefits package
• Values-driven culture emphasizing integrity, collaboration, urgency, and innovation

Recursion is a clinical stage TechBio company that decodes biology to radically improve lives through its Recursion OS platform, which generates one of the world's largest proprietary biological and chemical datasets and uses machine learning to advance the future of medicine.